Free tool · No account
Clinical trials for liver cancer
Liver cancer (hepatocellular carcinoma) trials weigh both the tumor and underlying liver function, so eligibility often turns on liver-health measures as much as the cancer itself.
1,021 recruiting trials. Showing a sample.
- recruitingPhase 2NCT07831993
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
This is a randomized, noncomparative, open-label, exploratory clinical study designed to evaluate the efficacy and safety of sintilimab in combination with NALIRIFOX or gemcitabine plus cisplatin (GP) as first-line treatment for patients with metastatic biliary tract cancer (B...
Listed by the study for Biliary Tract Cancer. Record updated 2026-09-21.
Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06910657
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cel...
Listed by the study for Hepatocellular Carcinoma. Record updated 2026-08-05.
Sponsored by ViroMissile, Inc.Full details on ClinicalTrials.gov → - recruitingNCT05517811
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as w...
Listed by the study for Liver Cancer. Record updated 2026-08-24.
Sponsored by University of Colorado, DenverFull details on ClinicalTrials.gov → - recruitingPhase 3NCT07594340
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
The purpose of this prospective, randomized, multicenter, controlled clinical study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared to transarterial chemoembolization (TACE) when both are combined with sintilimab and bevacizumab...
Listed by the study for Hepatocellular Carcinoma. Record updated 2026-05-22.
Sponsored by Binkui LiFull details on ClinicalTrials.gov → - recruitingPhase 2NCT05451043
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
A single-arm, interventional study combining Immunotherapy and propranolol with/without chemotherapy and propranolol 1. Pancreatic Cancer Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranol...
Listed by the study for Hepatocellular Cancer. Record updated 2025-06-26.
Sponsored by AHS Cancer Control AlbertaFull details on ClinicalTrials.gov → - recruitingNCT07142213
Effect and Mechanism of ALPPS Operation on Liver Regeneration
Hepatobiliary malignancies-principally hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)-are highly aggressive and often diagnosed at advanced stages. Curative-intent liver resection remains the standard for resectable disease; however, postoperative outcomes depend ...
Listed by the study for Hepato Cellular Carcinoma (HCC). Record updated 2025-08-26.
Sponsored by Haitao Zhao, MDFull details on ClinicalTrials.gov → - recruitingPhase 3NCT05201404
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Listed by the study for Hepatocellular Carcinoma. Record updated 2025-04-29.
Sponsored by Can-Fite BioPharmaFull details on ClinicalTrials.gov → - recruitingPhase 2NCT05690048
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
The interventional, randomized, placebo-controlled, double-blind phase II-trial FLORA will assess safety and immunogenicity of fecal microbiota transfer in combination with standard of care immunotherapy in advanced hepatocellular carcinoma (HCC) in a parallel group design. S...
Listed by the study for HCC - Hepatocellular Carcinoma. Record updated 2025-08-06.
Sponsored by Michael DillFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06218420
Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation
The aim of this trial is to carry out the first prospective multicentric study which evaluates the efficacy and the safety of SBRT in HCC patients enlisted for LT and not suitable for other bridging interventional treatments (RF or TACE). The incidence of hepatocellular carci...
Listed by the study for Hepatocellular Carcinoma. Record updated 2026-03-03.
Sponsored by Assistance Publique - Hôpitaux de ParisFull details on ClinicalTrials.gov → - recruitingNCT05623150
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic steatosis/Non-Alcoholic SteatoHepatitis. The investiga...
Listed by the study for Hepatocellular Carcinoma. Record updated 2026-04-16.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, FranceFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-11. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this liver cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.